This article was downloaded by: On: 22 January 2011 Access details: Access Details: Free Access Publisher Taylor & Francis Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



**To cite this Article** Cheng, Xing-Ye , Shi, Yue , Zheng, Shun-Liang , Jin, Wen and Sun, Hong(2008) 'Two new protoberberine quaternary alkaloids from *Corydalis yanhusuo*', Journal of Asian Natural Products Research, 10: 12, 1117 – 1121

To link to this Article: DOI: 10.1080/10286020802410615 URL: http://dx.doi.org/10.1080/10286020802410615

# PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: http://www.informaworld.com/terms-and-conditions-of-access.pdf

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.



# Two new protoberberine quaternary alkaloids from Corydalis yanhusuo

Xing-Ye Cheng, Yue Shi\*, Shun-Liang Zheng, Wen Jin and Hong Sun

Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

(Received 25 December 2007; final version received 7 July 2008)

Two new protoberberine quaternary alkaloids, 13-methyl-palmatrubine (1) and 13-methyldehydrocorydalmine (2), were isolated from the tubers of *Corydalis yanhusuo* W.T. Wang. 1 was isolated as a natural product for the first time, and 2 a new compound. Their structures were elucidated on the basis of spectroscopic evidence, especially 1D- and 2D-NMR experiments.

**Keywords:** *Corydalis yanhusuo*; protoberberine alkaloids; 13-methyl-palmatrubine; 13-methyl-dehydrocorydalmine

#### 1. Introduction

Corydalis yanhusuo W.T. Wang, called Rhizoma corydalis [1], has been employed in traditional Chinese medicine as an analgesic agent for treating spastic pain, abdominal pain, menstrual pain, and pain due to injuries [2]. It has also been widely used to promote blood circulation and treat coronary heart diseases [3,4]. Alkaloids are acknowledged to be the major active components in C. yanhusuo [5]. Among alkaloids, the main quaternary active principals of C. yanhusuo showed stronger activity than the tertiary ones [6,7]. However, up to now, very few quaternary alkaloids [8-10] have been isolated from it. In our search for new bioactive constituents of antimyocardial ischemia, two protoberberine quaternary alkaloids, 13-methyl-palmatrubine (1) and 13-methyl-dehydrocorydalmine (2), were isolated from the ethanolic extract of the tubers of C. yanhusuo.

2 was a new compound, and 1 was isolated as a natural product for the first time. Although 1 was synthesized, no spectral data were reported in the literature. The chemical structures of compounds 1 and 2 were elucidated based on spectral analysis (<sup>1</sup>H NMR, <sup>13</sup>C NMR, 2D-NMR, MS, UV, and IR). In this article, we present the isolation and structural determination of compounds 1 and 2.

### 2. Results and discussion

13-Methyl-dehydrocorydalmine (2) (Figure 1), obtained as yellowish needles, was positive to Dragendorff's reagent, revealing that it was an alkaloid compound. The UV absorption maxima at 336 and 266 nm and bathochromic shifts on adding alkali indicated the presence of a typical phenolic berberine-type alkaloid [11,12]. The HR-ESI-MS (positive) showed the molecular ion peak at m/z 352.1546 [M]<sup>+</sup>, supporting the molecular formula C<sub>21</sub>H<sub>22</sub>NO<sub>4</sub>. The <sup>1</sup>H and <sup>13</sup>C NMR spectral data (Tables 1 and 2) indicated that the molecule contained 15 aromatic carbons, including 3 methoxyls, 1 hydroxyl, 2 methylenes, and 1 methyl. The chemical and spectral properties have made it possible to assume that the alkaloid had a protoberberine quaternary alkaloid skeleton

<sup>\*</sup>Corresponding author. Email: yshi@implad.ac.cn

X-Y. Cheng et al.



Figure 1. Structures of 1, 2, and dehydro-corydaline.

similar to that of dehydrocorydaline except for a different substituted group linked with C-10 [10,13].

The carbon signal at  $\delta_C$  144.2 was assigned to C-9 for its HMBC correlations with H-8 at  $\delta_H$  9.68 and H-11 at  $\delta_H$  8.05.

Table 1.  $^{13}$ C NMR spectral data for compounds 1 (in CD<sub>3</sub>OD, 125 MHz), 2 (in CD<sub>3</sub>OD, 125 MHz), and dehydrocorydaline (in CDCl<sub>3</sub>, 75 MHz).

Position	1	2	Dehydrocorydaline [10]
1	116.6	116.5	113.9
2	149.5	149.9	147.6
3	152.5	153.4	150.5
4	112.6	112.6	110.7
4a	133.4	133.7	132.2
5	30.0	29.2	28.2
6	57.8	59.2	57.1
8	146.4	144.3	146.5
8a	121.3	123.8	121.7
9	163.9	144.2	151.3
10	151.2	150.8	146.3
11	124.1	132.1	125.4
12	107.2	122.7	119.7
12a	134.9	135.8	133.7
13	129.4	132.2	128.5
13a	134.7	138.3	136.3
13b	122.5	121.4	119.2
2-OMe	57.1*	57.2*	56.2*
3-OMe	57.3*	57.7*	56.5*
9-OMe		62.9	63.2
10-OMe	57.6		56.9*
13-Me	18.2	18.7	17.9

\*To be interchangeable.

The connectivity of methoxyl group to C-9 was explained by the HMBC correlation from  $\delta_{\rm H}$  4.16(3H, s, -OCH<sub>3</sub>) to C-9, which was further confirmed by the NOESY correlation of H-8 with 9-OMe. The hydroxyl was indicated to be connected to C-10 ( $\delta_{\rm C}$  150.8) because neither the HMBC correlation of C-10 with methoxyl group nor the NOESY cross-signal of methoxyl group with H-11 was observed (Figures 2 and 3). On the basis of these spectral data, **2** was determined to be 5,6-dihydro-10-hydroxy-2,3,9-trimethoxy-13-methyl-dibenzo[*a*,*g*] quinolizinium alkaloid, named 13-methyl-dehydrocorydalmine.

13-Methyl-palmatrubine (1) (Figure 1), obtained as red needles, was positive to Dragendorff's reagent, revealing that it was an alkaloid compound. The spectral data of 1 were almost identical to those of dehydrocorvdaline, except for the absence of one methoxyl signal. The connectivity of methoxyl group to C-10 ( $\delta_{\rm C}$  151.2) was explained by the HMBC correlations from the proton signal at  $\delta_{\rm H}$  3.89 (3H, s, -OCH<sub>3</sub>) to C-10 and verified by the NOESY correlation of the proton at  $\delta_{\rm H}$  3.89 (3H, s, -OCH<sub>3</sub>) with H-11 ( $\delta_{\rm H}$  7.58, 1H, d). The hydroxyl was suggested to be connected to C-9 ( $\delta_{\rm C}$  151.2) because neither the HMBC correlations of the methoxyl group with C-9 nor NOESY cross-signal of the methoxyl group with H-8 was observed. On the basis of these chemical and spectral properties, 1 was identified as 13-methyl-palmatrubine.

# 3. Experimental

#### 3.1 General experimental procedures

Melting points were measured on a Fisher-Johns melting-point apparatus and are uncorrected. UV and IR spectra were obtained on a TU-1810 UV–Vis spectrophotometer and a Nicolet Impact 410 infrared instrument with KBr pellets. NMR spectra were obtained on a Bruker Avance DRX-500 spectrometer at 500 MHz for <sup>1</sup>H NMR and 125 MHz for <sup>13</sup>C NMR, using CD<sub>3</sub>OD as a solvent and TMS as the internal standard. Chemical shifts were reported in  $\delta$  units (ppm) and coupling constants (*J*) in Hz. HR-ESI-MS were

Table 2. <sup>1</sup>H NMR spectral data for compounds **1** (in CD<sub>3</sub>OD, 500 MHz), **2** (in CD<sub>3</sub>OD, 500 MHz), and dehydrocorydaline (in CDCl<sub>3</sub>, 300 MHz).

Position	1	2	Dehydrocorydaline [10]
1	7.28 (1H, s)	7.38 (1H, s)	7.16 (1H, s)
2			
3			
4	7.03 (1H, s)	7.12 (1H, s)	6.93 (1H, s)
4a			
5	3.08 (2H, t)	3.19 (2H, t)	3.25 (2H, t)
6	4.53 (2H, t)	4.83 (2H, t)	5.30 (2H, br s)
8	9.35 (1H, s)	9.68 (1H, s)	10.68 (1H, s)
8a			
9			
10			
11	7.58 (1H, d, $J = 8.5$ Hz)	8.05 (1H, d, $J = 8.5$ Hz)	7.87 (1H, d, $J = 9.1$ Hz)
12	7.02 (1H, d, $J = 8.5$ Hz)	7.84 (1H, d, $J = 8.5$ Hz)	7.92 (1H, d, $J = 9.1$ Hz)
12a			
13			
13a			
13b			
2-OMe	3.89 (3H, s)	3.91 (3H, s)	3.94 (3H, s)
3-OMe	3.91 (3H, s)	3.95 (3H, s)	4.00 (3H, s)
9-OMe		4.16 (3H, s)	4.08 (3H, s)
10-OMe	3.89 (3H, s)		4.35 (3H, s)
13-Me	2.78 (3H, s)	3.01 (3H, s)	2.97 (3H, s)

\*To be interchangeable.

obtained on a VG-70SE mass spectrometer. D101 macroporous resin was purchased from the Chemical Plant of Nankai University (Tianjin, China). Silica gel (160–200 mesh; Qingdao Marine Chemical Inc., Qingdao, China), Sephadex LH-20 (GE Healthcare Bio-Sciences Co., Uppsala, Sweden), and RP-18 (YMC-GEL, ODS-A, 12 nm, S-50 µm; YMC Co., Kyoto, Japan) were used for column chromatography (CC), and silica gel  $GF_{254}$  (10–40 µm; Qingdao Marine Chemical Inc., Qingdao, China) for TLC.

## 3.2 Plant material

The dried tubers of *C. yanhusuo* W.T. Wang were collected from Hebei Province, China, in 2005, and were identified by Prof. Shi Yue.

OCH<sub>3</sub>

OH



Figure 2. Key HMBC correlations of 1 and 2.

*X-Y. Cheng* et al.



Figure 3. Key NOESY correlations of 1 and 2.

A voucher specimen of the sample (no. Y050124) is kept in the Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, China.

#### 3.3 Extraction and isolation

The dried tubers of C. yanhusuo (5 kg) were extracted with 80% ethanol under reflux three times and filtered. The combined filtrate was concentrated and dried under reduced pressure. The extract (300 g) was chromatographed over a D101 macroporous resin column with  $H_2O$  and 50% and 95% EtOH as eluants (50 L of each eluant). The fraction (58 g) eluted with 50% EtOH was subjected to silica gel CC (160-200 mesh, 1500 g) eluted with a gradient of CHCl<sub>3</sub>/MeOH (9:1, 5:1, 3:1, 1:1). The combined fractions (1 g) eluted with CHCl<sub>3</sub>/MeOH (9:1) were isolated on a Sephadex LH-20 column and eluted with MeOH to afford 1 (100 mg). The combined fraction (7 g) eluted with CHCl<sub>3</sub>/MeOH (5:1) was subjected to a reversed-phase CC (ODS-A, 12 nm, S-50 µm, 100 g) using MeOH/H<sub>2</sub>O (including 1.6% HAc and 0.4% triethylamine) (30:70, V/V) as eluant. Fractions 3-7were collected (200 mg in total) and further separated by preparative TLC  $(10 \text{ cm} \times 10)$ 

cm  $\times$  0.25 cm, silica gel F<sub>254</sub>, *n*-butanol/ HAc/H<sub>2</sub>O (4:5:1, V/V/V)) to give **2** (20 mg).

## 3.3.1 13-Methyl-palmatrubine (1)

Red needles, mp 175–176°C. UV (MeOH)  $\lambda_{max}$  (nm, log  $\varepsilon$ ): 232 (5.63), 272 (5.57), 338 (5.41); IR (KBr)  $\nu_{max}$  (cm<sup>-1</sup>): 1607, 1519, 1464, 1386, 1338, 1292, 1240, 1192, 1114; HR-ESI-MS (positive) *m/z*: 352.1558 [M]<sup>+</sup> (calcd for C<sub>21</sub>H<sub>22</sub>NO<sub>4</sub>, 352.1549); <sup>1</sup>H and <sup>13</sup>C NMR spectral data are listed in Table 1.

### 3.3.2 13-Methyl-dehydrocorydalmine (2)

Yellowish needles, mp 193–194°C. UV (MeOH)  $\lambda_{max}$  (nm, log  $\varepsilon$ ): 266 (5.49), 336 (5.39); IR (KBr)  $\nu_{max}$  (cm<sup>-1</sup>): 1604, 1521, 1459, 1382, 1346, 1281, 1210, 1173, 1104; HR-ESI-MS (positive) *m/z*: 352.1546 [M]<sup>+</sup> (calcd for C<sub>21</sub>H<sub>22</sub>NO<sub>4</sub>, 352.1549); <sup>1</sup>H and <sup>13</sup>C NMR spectral data are listed in Table 2.

#### Acknowledgements

This work was supported by a grant from special fund for the basic scientific research business of the statelevel scientific research institute of public welfare, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College. The authors thank the Analytical Center, Institute of Materia Medica Chinese Academy of Medical Sciences, and Peking Union Medical College for recording HR-ESI-MS. We are also thankful to the Beijing Institute of Microchemistry for recording NMR spectra.

## References

- [1] F.Y. Tang and A.G. Nie, *J. Clin. Exp.* **5**, 185 (2006).
- [2] W.C. Lenung and H. Zheng, *Prog. Neuropsychopharmacol. Biol.* 27, 775 (2003).
- [3] A.P. Sagare, Y.L. Lee, T.C. Lin, and C.C. Chen, *Plant Sci.* 160, 139 (2000).
- [4] L.Z. Zhang, J. Guiyang Med. Coll. 31, 280 (2006).
- [5] X.H. Xu, Z.T. Wang, G.D. Yu, B.F. Ruan, and J. Li, *J. Chin. Pharm. Univ.* 33, 483 (2002).

- [6] Y.Q. Qing and Q.Z. Yang, *Tianjin Med. J.* 10, 450 (1978).
- [7] B.R. Jang, Q.X. Wu, and H.L. Shi, Acta Pharm. Sin. 17, 61 (1982).
- [8] B.Z. Chen, W.Y. Lian, R.Z. Feng, and G.Y. Fu, *Chin. Tradit. Herb Drugs* 17, 150 (1986).
- [9] X.Y. Fu, W.Z. Liang, and G.S. Tu, Acta Pharm. Sin. 21, 447 (1986).
- [10] S.Q. Tong, J.Z. Yang, and J. Liq, J. Liq. Chromatogr. Related 28, 2979 (2005).
- [11] M. Shamma, *The Isoquinoline Alkaloids*, (Academic Press, New York, NY, 1972).
- [12] Y.C. Chia, F.R. Chang, C.M. Li, and Y.C. Wu, *Phytochemistry* 48, 367 (1998).
- [13] L. Grycova, J. Dostal, and R. Marek, *Phytochemistry* 68, 150 (2007).